Dostarlimab is a medicine for Cancer treatment. In mismatch repair deficiency new cells are formed rapidly which the body is not able to control & which leads to cancer. 10 percent of rectal cancers have this deficiency problem. This medicine acts by blocking the PD-1 protein in cancer cells & cancer cells are unable to bypass the body’s defense system & T-1 cells do their work.
Advantages of this treatment
Researchers have found that by taking this treatment cancer in all the patients was cured. This is a very significant development where trials have been done by treating cancer with this medicine. After treatment, other organs of the body were not affected.
Causes of normal cancer treatment
During normal cancer treatment, a patient must go through various stages like surgery, radiation & chemotherapy which have damaging effects on the health. The cancer patient is already weak. His health is badly affected by radiation, surgery & chemotherapy, etc.
Cancer is a challenging disease
There is no doubt that cancer is a very challenging disease. In a clinical trial in the USA, rectal cancer was fully treated with this medicine. In this clinical trial, Dostarlimab was given to 18 patients for 6 months and after 6 months cancer was totally cured in all the patients. Every patient was given 8 doses. This trial was published in the New England Journal of medicine.
Costly treatment
The dose of this medicine is 500 mg, and its cost is approximately 8.5 lakh. Although it is a very costly treatment, we are hopeful that in the future its other derivatives will be made, and cancer treatment will be more economical.
Clinical trial for Cancer patients
This clinical trial was done on rectal cancer patients. In rectal cancer, the patients had mismatch repair deficiency due to which new cells are generated and the body cannot cure them. 10% of rectal cancer patients have mismatch repair deficiency end this drug acts on the mismatch repair deficiency and cures the patients. Its trial has been trying for rectal cancer but soon it will be trialed on other types of cancers also and we are hopeful that it will act on other types of cancers too.
